Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Clozapine: Antipsychotic
Dose: as per patients condition
Frequency: As per Maudsley guidelines
Route of administration: oral
Duration: as per patients condition
Control Intervention1: R
Sponsors
Government medical college and hospital
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia according to ICD-11 Drug naïve/ not on any antipsychotic drug for more than 2 weeks.
Exclusion criteria
Exclusion criteria: Patient on immunosuppressants Patients with overt infection in the past 2 weeks, hematological disorders, chronic liver or kidney disease, autoimmune disorders and chronic inflammatory disease Patient on antibiotics (chloramphenicol, tetracycline, rifampicin, polymyxin b, nitrofurantoin) Patients with known immunodeficiency disorder Patients with epilepsy Patients unable to tolerate clozapine Patients with agranulocytosis or granulocytopenia Patients with paralytic ileus, CNS depression, myeloproliferative disorder Patients with substance use disorder except tobacco and caffeine Pregnant and lactating women Patient who have received depot antipsychotics in the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the levels of serum immunoglobulins and interleukins in patients of schizophrenia on clozapine at baseline and at 6 weeks and 12 weeks. To study the correlation of clozapine response with levels of serum immunoglobulins and interleukins in patients of schizophrenia. Timepoint: To assess the levels of serum immunoglobulins and interleukins in patients of schizophrenia on clozapine at baseline and at 6 weeks and 12 weeks. To study the correlation of clozapine response with levels of serum immunoglobulins and interleukins in patients of schizophrenia. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the levels of serum immunoglobulins and interleukins in patients of schizophrenia on clozapine at baseline and at 6 weeks and 12 weeks. To study the correlation of clozapine response with levels of serum immunoglobulins and interleukins in patients of schizophrenia. Timepoint: To assess the levels of serum immunoglobulins and interleukins in patients of schizophrenia on clozapine at baseline and at 6 weeks and 12 weeks. To study the correlation of clozapine response with levels of serum immunoglobulins and interleukins in patients of schizophrenia. | — |
Countries
India
Contacts
Public ContactDr B S Chavan
Government medical college and hospital
Outcome results
None listed